{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:01:26Z","timestamp":1790874086007,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:18:20Z","timestamp":1784330300000},"page":"e1187-e1201.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study"],"prefix":"10.1016","volume":"26","author":[{"given":"L\u00e9opoldine","family":"Lapierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6248-566X","authenticated-orcid":false,"given":"Lucie","family":"Laemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Rigolot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-8377","authenticated-orcid":false,"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Higu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9161-5141","authenticated-orcid":false,"given":"Anne","family":"Banos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-6157","authenticated-orcid":false,"given":"Guillaume","family":"B\u00e9ziat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Jeddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6518-3870","authenticated-orcid":false,"given":"Benoit","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Calmettes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Gadaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-2071","authenticated-orcid":false,"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Ghenim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Laboure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Salvado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9phine","family":"Thomazeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Balardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-4948","authenticated-orcid":false,"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-3307","authenticated-orcid":false,"given":"Alban","family":"Canali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Mougenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baraniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"de Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-0395","authenticated-orcid":false,"given":"Pierre","family":"Bories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Largeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Belhabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1486-9873","authenticated-orcid":false,"given":"Urbain","family":"Tauveron-Jalenques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8721","authenticated-orcid":false,"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vergez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2026.07.007_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2026.07.007_bib0002","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.07.007_bib0003","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.007_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2026.07.007_bib0005","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.clml.2026.07.007_bib0006","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-024-05891-w","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?","volume":"104","author":"Solana-Altabella","year":"2025","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2026.07.007_bib0007","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.07.007_bib0008","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.07.007_bib0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.clml.2026.07.007_bib0010","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with Venetoclax and Azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.07.007_bib0011","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.07.007_bib0012","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.07.007_bib0013","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2024-207764","article-title":"Measurable residual disease (MRD) determinants, kinetics and its impact on survival in patients treated with azacitidine and venetoclax for acute myeloid leukemia in frontline setting: a multicentric study from French Auraml Group","volume":"144","author":"Heiblig","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.07.007_bib0014","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2026.07.007_bib0015","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2026.07.007_bib0016","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.07.007_bib0017","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cyto.a.23897","article-title":"An R-derived FlowSOM process to analyze unsupervised clustering of normal and malignant Human bone marrow classical flow cytometry data","volume":"95","author":"Lacombe","year":"2019","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.clml.2026.07.007_bib0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-22-2237","article-title":"Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia","volume":"29","author":"Canali","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clml.2026.07.007_bib0019","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.07.007_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.27515","article-title":"The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia","volume":"100","author":"DiNardo","year":"2025","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2026.07.007_bib0021","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"D\u00f6hner","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2026.07.007_bib0022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.07.007_bib0023","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3324\/haematol.2024.285225","article-title":"Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens","volume":"109","author":"Baden","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2026.07.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"12","key":"10.1016\/j.clml.2026.07.007_bib0025","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.23848","article-title":"Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network","volume":"89","author":"Bories","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.07.007_bib0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-022-00698-2","article-title":"G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial","volume":"12","author":"Stopka","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.07.007_bib0027","first-page":"275","article-title":"The role of growth factors in the activity of pharmacological differentiation agents","volume":"13","author":"Matsui","year":"2002","journal-title":"Cell Growth Differ"},{"issue":"8","key":"10.1016\/j.clml.2026.07.007_bib0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa025406","article-title":"Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.07.007_bib0029","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2025-769","article-title":"Vag regimen drives immune reprogramming and superior remission in older\/unfit AML patients","volume":"146","author":"Huo","year":"2025","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:16:25Z","timestamp":1790871385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002120"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}